Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8193648 | 0.95 | ALDH1A1 (0.50) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL12869546 | 0.93 | ALDH1A1 (0.49) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL12258804 | 0.93 | ALDH1A1 (0.51) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL5240027 | 0.84 | KDM4E (0.63) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL7876466 | 0.84 | ALDH1A1 (0.46) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL8437435 | 0.82 | ALDH1A1 (0.55) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL21844010 | 0.81 | ALDH1A1 (0.40) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL15461461 | 0.79 | ALDH1A1 (0.37) | ALDH1A1CYP2D6 | |
| SCHEMBL12276350 | 0.79 | ALDH1A1 (0.34) | ALDH1A1CYP2D6 | |
| SCHEMBL21916515 | 0.78 | ALDH1A1 (0.41) | ALDH1A1CYP2D6KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | ALDH1A1 1556/4885CYP2D6 865/4885KDM4E 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.